WUH: Prose: A prospective Observational study of adult patients receiving Dupixent for Atopic Dermatitis
Brief description of study
This study is conducted to observe the real-world patient characteristics, use, effectiveness and safety of the drug DUPIXENT, also known as dupilumab by its generic name. DUPIXENT is approved by the Food and Drugs Administration (FDA) for the treatment of moderate to severe atopic dermatitis (AD), commonly known as eczema. The main purpose of this study is to collect long-term data on adolescent and adult patients with moderate to severe atopic dermatitis who received treatment with DUPIXENT.
Clinical Study Identifier: s18-01441
ClinicalTrials.gov Identifier: NCT03428646
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
